https://www.biopharmawatch.com/news/BMY/one-mind-music-festival-2026 BiopharmaWatch en 2026-08-19T13:05:00.000Z FESTIVAL ANNOUNCEMENT: 32nd Annual One Mind Music Festival Presented by Bank of America and Bristol Myers Squibb https://www.biopharmawatch.com/news/INCR/intercure-reverse-share-split-nasdaq-compliance BiopharmaWatch en 2026-08-19T13:00:00.000Z InterCure Ltd. Announces 1-for-5 Reverse Share Split https://www.biopharmawatch.com/news/HSCS/fortitude-invests-1-million-heartsciences-premium BiopharmaWatch en 2026-08-19T13:00:00.000Z Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration https://www.biopharmawatch.com/news/REVB/revelation-biosciences-avance-clinical-phase-2-3-study BiopharmaWatch en 2026-08-19T13:00:00.000Z Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study https://www.biopharmawatch.com/news/FEMY/femasys-fda-approval-fembloc BiopharmaWatch en 2026-08-19T13:00:00.000Z Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® https://www.biopharmawatch.com/news/BMY/hematogenix-mm-mrd-assay-fda-approval-zenbexus BiopharmaWatch en 2026-08-19T12:32:00.000Z Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fiscal-2026-revenue-growth BiopharmaWatch en 2026-08-19T12:30:00.000Z Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-merger-update-phase-2-trial BiopharmaWatch en 2026-08-19T12:26:00.000Z Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/MXCT/maxcyte-launches-change-seq-be-one-seq-be-off-target-assays BiopharmaWatch en 2026-08-19T12:05:00.000Z MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies https://www.biopharmawatch.com/news/AEON/aeon-reports-expanded-structural-data-abp-450-botox BiopharmaWatch en 2026-08-19T12:00:31.000Z AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® https://www.biopharmawatch.com/news/AEON/aeon-reports-expanded-structural-data-abp-450-botox BiopharmaWatch en 2026-08-19T12:00:31.000Z AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® https://www.biopharmawatch.com/news/BAX/baxter-appoints-john-rogers-cfo BiopharmaWatch en 2026-08-19T12:00:00.000Z Baxter Appoints John Rogers Chief Financial Officer https://www.biopharmawatch.com/news/HUMA/humacyte-lancet-digital-health-v007-trial-results BiopharmaWatch en 2026-08-19T12:00:00.000Z Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results https://www.biopharmawatch.com/news/MNPR/monopar-appoints-dr-kent-alxn1840-presentations-aasld-2026 BiopharmaWatch en 2026-08-19T12:00:00.000Z Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026 https://www.biopharmawatch.com/news/ZEPP/zepp-health-q2-2026-financial-results-report BiopharmaWatch en 2026-08-19T11:30:00.000Z Zepp Health Corporation to Report Second Quarter 2026 Financial Results on September 1, 2026 https://www.biopharmawatch.com/news/ACB/aurora-cannabis-shareholders-no-action-curaleaf-bid BiopharmaWatch en 2026-08-19T11:05:00.000Z AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC. https://www.biopharmawatch.com/news/SGHT/tearcare-fda-indication-improves-meibomian-gland-function BiopharmaWatch en 2026-08-19T11:05:00.000Z TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-licenses-kio-301-south-korea BiopharmaWatch en 2026-08-19T11:00:00.000Z Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation https://www.biopharmawatch.com/news/GKOS/glaukos-participation-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-19T11:00:00.000Z Glaukos Announces Participation in Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/PLSM/pulsenmore-home-ultrasound-expansion-ichilov BiopharmaWatch en 2026-08-19T11:00:00.000Z Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring https://www.biopharmawatch.com/news/NSRX/nasus-pharma-cfo-transition BiopharmaWatch en 2026-08-19T11:00:00.000Z Nasus Pharma Announces Transition of Chief Financial Officer https://www.biopharmawatch.com/news/MRK/merck-moderna-phase-3-int-trial-results BiopharmaWatch en 2026-08-19T10:45:00.000Z Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma https://www.biopharmawatch.com/news/IDYA/ideaya-genentech-collaboration-kras-cancer-trial BiopharmaWatch en 2026-08-19T10:00:00.000Z IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-08-17 BiopharmaWatch en 2026-08-19T07:15:33.495Z Upcoming Phase 3 Readouts: Key Insights and Expectations https://www.biopharmawatch.com/news/PBM/psyence-biomed-accelerate-ibogaine-development BiopharmaWatch en 2026-08-19T06:27:33.000Z Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development https://www.biopharmawatch.com/news/NVS/novartis-esc-congress-2026-cardiovascular-leadership BiopharmaWatch en 2026-08-19T05:15:00.000Z Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies https://www.biopharmawatch.com/news/IMCC/im-cannabis-30-1-share-consolidation-nasdaq-compliance BiopharmaWatch en 2026-08-18T21:01:00.000Z IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance https://www.biopharmawatch.com/news/AUNA/auna-announces-2q26-financial-results BiopharmaWatch en 2026-08-18T20:57:00.000Z Auna Announces 2Q26 Financial Results https://www.biopharmawatch.com/news/BAX/baxter-upsized-cash-tender-offers-pricing BiopharmaWatch en 2026-08-18T20:56:00.000Z Baxter Announces Pricing for Its Upsized Cash Tender Offers https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-kol-event-parp-inhibitors-oncology BiopharmaWatch en 2026-08-18T20:15:00.000Z Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald https://www.biopharmawatch.com/news/SILO/silo-pharma-canadian-patent-ptsd-treatment BiopharmaWatch en 2026-08-18T20:15:00.000Z Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment https://www.biopharmawatch.com/news/ONC/beone-medicines-extend-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T20:09:00.000Z Samenvatting: BeOne Medicines, BeOne Care Foundation en The Max Foundation verlengen samenwerking om toegang tot BRUKINSA® voor de behandeling van chronische lymfatische leukemie in lage- en middeninkomenslanden te vergroten https://www.biopharmawatch.com/news/IRIX/iridex-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-18T20:05:00.000Z Iridex Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-350-million-offering BiopharmaWatch en 2026-08-18T20:01:00.000Z Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock https://www.biopharmawatch.com/news/HALO/halozyme-appoints-dannielle-appelhans-board-directors BiopharmaWatch en 2026-08-18T20:01:00.000Z Halozyme Appoints Dannielle Appelhans to its Board of Directors https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-reverse-stock-split BiopharmaWatch en 2026-08-18T20:01:00.000Z Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T19:56:00.000Z BeOne Medicines ومؤسسة BeOne Care Foundation ومؤسسة The Max Foundation تجدد شراكتها لتوسيع نطاق الوصول إلى BRUKINSA®‎ لعلاج سرطان الدم الليمفاوي المزمن في البلدان ذات الدخل المنخفض والمتوسط https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-collaboration-brukinsa-access BiopharmaWatch en 2026-08-18T19:18:00.000Z Riassunto: BeOne Medicines, BeOne Care Foundation e The Max Foundation rinnovano la collaborazione per ampliare l'accesso a BRUKINSA® per il trattamento della leucemia linfatica cronica nei Paesi a reddito medio-basso https://www.biopharmawatch.com/news/BLLN/cfDNA-fetal-risk-assessment-general-risk-pregnancies BiopharmaWatch en 2026-08-18T16:08:00.000Z Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions https://www.biopharmawatch.com/news/ELUT/cellution-biologics-acquires-simpliderm-elutia BiopharmaWatch en 2026-08-18T15:19:00.000Z Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. https://www.biopharmawatch.com/news/NTHI/neonc-technologies-insider-buying-and-clinical-success BiopharmaWatch en 2026-08-18T14:18:00.000Z NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t https://www.biopharmawatch.com/news/CODX/co-diagnostics-medical-devices-innovation-roundtable BiopharmaWatch en 2026-08-18T13:30:00.000Z Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event https://www.biopharmawatch.com/news/DARE/dare-bioscience-ceo-forbes-50-over-50-innovation BiopharmaWatch en 2026-08-18T13:02:00.000Z DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List https://www.biopharmawatch.com/news/CON/concentra-appoints-dr-jill-rosenthal-cmo BiopharmaWatch en 2026-08-18T13:00:00.000Z Concentra Appoints Dr. Jill Rosenthal as Chief Medical Officer to Advance Clinical Innovation and Workforce Health https://www.biopharmawatch.com/news/UNH/unitedhealthcare-expands-behavioral-coaching-access BiopharmaWatch en 2026-08-18T13:00:00.000Z UnitedHealthcare Expands Access to Child and Family Behavioral Coaching to 13 Million Commercial Members https://www.biopharmawatch.com/news/GEHC/ge-healthcare-appoints-william-grogan-cfo BiopharmaWatch en 2026-08-18T13:00:00.000Z GE HealthCare appoints William Grogan as Chief Financial Officer https://www.biopharmawatch.com/news/DGX/whoop-advanced-labs-access-without-membership BiopharmaWatch en 2026-08-18T13:00:00.000Z WHOOP Makes Advanced Labs Available Without a Wearable Membership https://www.biopharmawatch.com/news/BAX/baxter-early-tender-results-upsizing-offers BiopharmaWatch en 2026-08-18T13:00:00.000Z Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers https://www.biopharmawatch.com/news/PRVA/privia-health-appoints-opella-ernest-board-directors BiopharmaWatch en 2026-08-18T13:00:00.000Z Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors https://www.biopharmawatch.com/news/ONCY/oncolytics-fda-registrational-path-colorectal-cancer BiopharmaWatch en 2026-08-18T13:00:00.000Z Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer https://www.biopharmawatch.com/news/POCI/precision-optics-appoints-peter-thier-svp-sales-marketing BiopharmaWatch en 2026-08-18T13:00:00.000Z Precision Optics Appoints Peter Thier as Senior Vice President of Sales and Marketing https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-aktx-101-urothelial-cancer-data BiopharmaWatch en 2026-08-18T12:53:00.000Z Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-hc-wainwright-conference BiopharmaWatch en 2026-08-18T12:45:00.000Z Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-in-house-lab-iowa-city BiopharmaWatch en 2026-08-18T12:35:00.000Z Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City https://www.biopharmawatch.com/news/QTI/qt-imaging-mid-year-2026-ceo-letter BiopharmaWatch en 2026-08-18T12:30:00.000Z QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders https://www.biopharmawatch.com/news/FBLG/fibrobiologics-chondrocyte-spheroids-cartilage-repair BiopharmaWatch en 2026-08-18T12:30:00.000Z FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-fda-fast-track-pln-101095 BiopharmaWatch en 2026-08-18T12:30:00.000Z Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-phase-1b-clinical-study-prp BiopharmaWatch en 2026-08-18T12:30:00.000Z Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP https://www.biopharmawatch.com/news/FEED/envue-medical-uroshield-distribution-agreement BiopharmaWatch en 2026-08-18T12:30:00.000Z ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-regenerative-aesthetics-market-growth BiopharmaWatch en 2026-08-18T12:30:00.000Z Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration https://www.biopharmawatch.com/news/RKTO/rocket-one-launches-drone-swarm-emulation-platform BiopharmaWatch en 2026-08-18T12:08:00.000Z Rocket One Launches Swarm Stage AI Drone-Swarm Threat Emulation Platform for U.S. Military Counter-UAS https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-financing-cad5-4-million BiopharmaWatch en 2026-08-18T12:06:00.000Z SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million https://www.biopharmawatch.com/news/HUMA/first-commercial-symvess-implantation-arizona BiopharmaWatch en 2026-08-18T12:00:00.000Z Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” https://www.biopharmawatch.com/news/ENTX/entera-appoints-riccardo-paolo-camisasca-cmo BiopharmaWatch en 2026-08-18T12:00:00.000Z Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation https://www.biopharmawatch.com/news/BIAF/bioaffinity-avmedical-distribution-agreement-cypath-lung BiopharmaWatch en 2026-08-18T12:00:00.000Z bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung https://www.biopharmawatch.com/news/TRLV/trulieve-closing-bell-nyse-cannabis-company BiopharmaWatch en 2026-08-18T12:00:00.000Z Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE https://www.biopharmawatch.com/news/GRFS/kedrion-grifols-agreement-extension-gammaked BiopharmaWatch en 2026-08-18T12:00:00.000Z Kedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED® https://www.biopharmawatch.com/news/ABBV/abbvie-immunology-scholarship-2026-recipients BiopharmaWatch en 2026-08-18T12:00:00.000Z AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-phase-1-2a-lithium-imaging-data-presentation BiopharmaWatch en 2026-08-18T12:00:00.000Z Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain https://www.biopharmawatch.com/news/ELUT/elutia-simpliderm-sale-nxt-41x-launch BiopharmaWatch en 2026-08-18T12:00:00.000Z Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch https://www.biopharmawatch.com/news/RCEL/avitamedical-permeaderm-study-results-economic-advantage BiopharmaWatch en 2026-08-18T11:45:00.000Z AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-regina-donohue-suresh-durgam BiopharmaWatch en 2026-08-18T11:30:32.000Z Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board https://www.biopharmawatch.com/news/AMLX/amylyx-phase-3-lucidity-trial-avexitide-results BiopharmaWatch en 2026-08-18T11:00:00.000Z Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia https://www.biopharmawatch.com/news/LH/labcorp-nachc-strategic-alliance-community-health BiopharmaWatch en 2026-08-18T11:00:00.000Z Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health https://www.biopharmawatch.com/news/GNPX/genprex-manufacturing-scale-up-diabetes-gene-therapy BiopharmaWatch en 2026-08-18T11:00:00.000Z Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy https://www.biopharmawatch.com/news/BLSM/blossomhill-fda-fast-track-bh-30643 BiopharmaWatch en 2026-08-18T11:00:00.000Z BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC https://www.biopharmawatch.com/news/IMTX/immatics-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-18T11:00:00.000Z Immatics Announces Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/PFE/pfizer-settlement-depo-provera-litigation BiopharmaWatch en 2026-08-18T10:15:00.000Z Legal Bay Pre-Settlement Funding Reports Pfizer Agrees to Settle Depo-Provera Birth Control Litigation https://www.biopharmawatch.com/news/ONC/beone-medicines-renews-partnership-brukinsa-access BiopharmaWatch en 2026-08-18T10:00:00.000Z BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries https://www.biopharmawatch.com/news/NUTX/nutex-health-opens-west-little-rock-emergency-hospital BiopharmaWatch en 2026-08-18T09:30:00.000Z NUTEX HEALTH OPENS WEST LITTLE ROCK EMERGENCY HOSPITAL IN ARKANSAS https://www.biopharmawatch.com/news/SNN/smith-nephew-imperial-college-robotic-surgery-innovation BiopharmaWatch en 2026-08-18T07:01:00.000Z Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics https://www.biopharmawatch.com/news/CYPH/cypherpunk-technologies-launches-zcash-mining-fleet BiopharmaWatch en 2026-08-18T00:00:00.000Z Cypherpunk Technologies Launches World's Largest Zcash Mining Fleet Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk") today announced the launch of Cypherpunk Mining, which is now the largest Zcash mining... https://www.biopharmawatch.com/news/CHRS/coherus-oncology-special-dividend-cvr BiopharmaWatch en 2026-08-17T21:33:00.000Z Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights https://www.biopharmawatch.com/news/BDX/bd-appoints-gary-sorsher-chief-quality-officer BiopharmaWatch en 2026-08-17T20:30:00.000Z BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-inducement-grant-nasdaq-rule-5635c4 BiopharmaWatch en 2026-08-17T20:28:00.000Z Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/DCGO/docgo-announces-q2-2026-results BiopharmaWatch en 2026-08-17T20:20:00.000Z DocGo Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/IQV/iqvia-ranked-no-1-pharmaceutical-technology-provider BiopharmaWatch en 2026-08-17T20:15:00.000Z IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group https://www.biopharmawatch.com/news/CVS/cvs-health-board-changes-2026 BiopharmaWatch en 2026-08-17T20:15:00.000Z CVS Health Announces Board Changes https://www.biopharmawatch.com/news/POCI/precision-optics-lytham-partners-summit-2026 BiopharmaWatch en 2026-08-17T20:15:00.000Z Precision Optics to Participate in the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, 2026 https://www.biopharmawatch.com/news/RMD/resmed-appoints-carol-burt-lead-director BiopharmaWatch en 2026-08-17T20:10:00.000Z Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor https://www.biopharmawatch.com/news/AMLX/amylyx-announces-topline-results-phase-3-lucidity-trial BiopharmaWatch en 2026-08-17T20:01:00.000Z Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026 https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-public-offering-closure BiopharmaWatch en 2026-08-17T20:01:00.000Z Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/MOH/molina-donates-food-kitchen-saginaw BiopharmaWatch en 2026-08-17T19:00:00.000Z The MolinaCares Accord and Molina Healthcare of Michigan Donate $100,000 to Support Construction of a New Food Kitchen in Saginaw County https://www.biopharmawatch.com/news/VOGX/vogenx-ipo-813-million-jones-trading BiopharmaWatch en 2026-08-17T16:25:00.000Z Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering